White Plains, NY, United States of America

Shi-Xian Deng

USPTO Granted Patents = 25 (Patent Applications = 12)

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 2 (Patent Applications = 6)

Average Co-Inventor Count = 4.7

ph-index = 3

Forward Citations = 21(Granted Patents)

Company Filing History:

Ny State Psychiatric Institute

patents

2 out of 3,370

University of Michigan

patents

4. 2 out of 877

University of Kentucky Research Foundation

patents

where one patent can have more than one assignee

Years Active: 2008-2024

Loading Chart...

25 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12168664 - Triazolopyrimidines, their preparation and use (2024-12-17),

2. 11459306 - Compounds, compositions, and methods for treating T-cell acute lymphoblastic leukemia (2022-10-04),

3. 11261199 - Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies (2022-03-01),

4. 11230558 - Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies (2022-01-25),

5. 11008341 - Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies (2021-05-18),

6. 10882863 - Compounds for reducing c-Myc in c-Myc overexpressing cancers background (2021-01-05),

7. 10865214 - Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies (2020-12-15),

8. 10487091 - Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies (2019-11-26),

9. 10485845 - Neuronal pain pathway (2019-11-26),

10. 10098975 - Labeled pkg-1-alpha-binding compounds and their use in imaging and quantifying pain (2018-10-16),

11. 10005732 - Potent non-urea inhibitors of soluble epoxide hydrolase (2018-06-26),

12. 9981025 - Anti-drug vaccines (2018-05-29),

13. 9896420 - N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation (2018-02-20),

14. 9402826 - Neuronal pain pathway modulators (2016-08-02),

15. 9200265 - Anti-cocaine compositions and treatment (2015-12-01),

Title: Shi-Xian Deng: Innovator in Pharmaceutical Chemistry

Introduction: Shi-Xian Deng is a prominent inventor based in White Plains, NY, known for his significant contributions to pharmaceutical chemistry. With 25 patents to his name, his innovations focus on compounds that play vital roles in the treatment of cancers, specifically leukemia and non-Hodgkin lymphoma.

Latest Patents: Among his latest patents is the invention of Triazolopyrimidines, which outlines a compound structure that offers potential therapeutic benefits. The patent details specific configurations of the compound where R groups can be various substituents and includes a description of pharmaceutically acceptable salts. Another crucial patent highlights compounds, compositions, and methods for treating T-cell acute lymphoblastic leukemia. This disclosure not only provides innovative compounds for treatment but also addresses methods of administering these compounds to patients. Furthermore, it discusses compounds that inhibit certain phosphoinositide 3-kinase isoforms and their application for treating non-Hodgkin lymphoma.

Career Highlights: Shi-Xian Deng has worked at notable institutions, including Columbia University in the City of New York and the New York State Psychiatric Institute, where he has made significant research contributions. His deep knowledge of chemical compounds and their uses in medical treatments has led him to become a leading figure in the field.

Collaborations: Collaboration is a key aspect of his work, and he has partnered with esteemed colleagues such as Donald W. Landry and Kirsten Alison Rinderspacher. These collaborations have strengthened his research output and expanded the reach of his innovations.

Conclusion: With a prolific number of patents and impactful collaborations, Shi-Xian Deng continues to shape the future of pharmaceutical advancements. His focus on developing effective treatments for serious health conditions exemplifies the role of inventors in driving innovation in the medical field.

This text is generated by artificial intelligence and may not be accurate.